Prices are updated after-hours

Health Technology 2021 - 02 - 08

Aerie Pharmaceuticals, Inc.

AERI | $15.25 0.0%

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (13.48% volume)
Earnings Calendar: 2023-02-23
Market Cap: $ 753,615,457
http://www.aeriepharma.com
Sec Filling | Patents | 380 employees

(US) Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.

eye treatment

Drugs

Rhopressa (netarsudil)
Rocklatan (netarsudil and latanoprost ophthalmic solution, 0.02%/0.005%)

add to watch list Paper trade email alert is off

Evelo Biosciences, Inc.

EVLO | $0.3165 -87.39% 710K

Health Technology

(0.0% 1d) (0.0% 1m) (-89.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-17.9% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 6,008,068
http://www.evelobio.com
Sec Filling | Patents | 98 employees

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of monoclonal microbials, a modality of oral biologic medicines. It has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.

cancer msa treatment

add to watch list Paper trade email alert is off

BELLUS Health Inc.

BLU | $14.74 0.03% 0

Health Technology

(0.0% 1d) (0.0% 1m) (1.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (688.59% volume)
Earnings Calendar: 2023-08-09
Market Cap: $ 1,869,211,386
http://www.bellushealth.com
Sec Filling | Patents | 40 employees

(CA) BELLUS Health, Inc. is a biopharmaceutical development company which engages in the research and development of novel therapeutics for the treatment of chronic cough and other hypersensitisation disorders. Its product, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

chronic cough hypersensitisation treatment

add to watch list Paper trade email alert is off

Allena Pharmaceuticals, Inc.

ALNA | $0.075 -12.0%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (431.58% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 9,156,242
http://www.allenapharma.com
Sec Filling | Patents | 83 employees

(United States) Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults; and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Newton, MA.

kidney diseases kidney stones treatment kidney

add to watch list Paper trade email alert is off

Apollo Endosurgery, Inc.

APEN | $10.0 0.75% 1.7M

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-53.84% volume)
Earnings Calendar: 2023-05-02
Market Cap: $ 579,719,190
http://apolloendo.com
Sec Filling | Patents | 217 employees

Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, OverStitch Sx Endoscopic Suturing System, and Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas; inadvertent perforation of the GI tract; tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon; the treatment of swallowing disorders; esophageal stent fixation and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.

gastrointestinal endoscopy treatment

add to watch list Paper trade email alert is off

Applied Genetic Technologies Corporation

AGTC | News | $0.3936 1.23% 0.0%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-80.43% volume)
Earnings Calendar: 2022-11-08
Market Cap:
http://www.agtc.com
Sec Filling | Patents | 83 employees

(US) Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the development of gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. It has clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL.

gene therapies genetic clinical trials

add to watch list Paper trade email alert is off

ChemoCentryx, Inc.

CCXI | News | $51.99 -0.04%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (160.14% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 3,709,791,785
http://www.chemocentryx.com
Sec Filling | Patents | 82 employees

(US) ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.

cancer autoimmunity

add to watch list Paper trade email alert is off

Codiak BioSciences, Inc.

CDAK | $0.057 -55.99% -131.25% 0

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-0.9% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 2,099,289
http://www.codiakbio.com
Sec Filling | Patents | 105 employees

(United States) Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. The company was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA.

diagnostics

add to watch list Paper trade email alert is off

AVEO Pharmaceuticals, Inc.

AVEO | $15.0 0.0% 0

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2023-03-13
Market Cap: $ 521,446,905
http://www.aveooncology.com
Sec Filling | Patents | 19 employees

(US) AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

urea

add to watch list Paper trade email alert is off

Axcella Health Inc.

AXLA | $4.58 -56.33% 42K

Health Technology

(0.0% 1d) (0.0% 1m) (965.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1982.28% volume)
Earnings Calendar: 2023-10-31
Market Cap: $ 13,500,512
http://www.axcellahealth.com
Sec Filling | Patents | 64 employees

Axcella Health, Inc. is a biotechnology company, which engages in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. Its product pipeline includes AXA1665, AXA1125, AXA1957, AXA2678, and AXA4010. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.

metabolic

add to watch list Paper trade email alert is off

Ayala Pharmaceuticals, Inc.

AYLA | $0.5036 5.84% -0.7% 0

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (15.3% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 7,463,718
http://www.ayalapharma.com
Sec Filling | Patents | 29 employees

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology. It is focused on the development and commercialization of small molecule therapeutics for patients suffering from rare and aggressive cancers. It also involved in in precision oncology, targeted therapy, drug development, companion diagnostics, and biomarkers. The company was founded in November 2017 and is headquartered in Rehovot, Israel.

cancer israel diagnostics

add to watch list Paper trade email alert is off

Baudax Bio, Inc.

BXRX | $0.1864 -54.35% 330K

Health Technology

(0.0% 1d) (0.0% 1m) (-91.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-0.34% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 1,710,656
http://www.baudaxbio.com
Sec Filling | Patents | 25 employees

Baudax Bio, Inc. is a pharmaceutical company focusing on developing and commercializing products for acute care settings. The company was founded in 2015 and is headquartered in Malvern, PA.

Drugs

Anjeso (meloxicam)

add to watch list Paper trade email alert is off

Concert Pharmaceuticals, Inc.

CNCE | $8.37 0.36% 0

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (16.76% volume)
Earnings Calendar: 2023-03-02
Market Cap: $ 520,711,745
http://www.concertpharma.com
Sec Filling | Patents | 70 employees

(US) Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

autoimmunity nervous system molecule drugs

add to watch list Paper trade email alert is off

Evogene Ltd.

EVGN | $0.7 -13.64% 63K

Health Technology

(0.0% 1d) (-4.4% 1m) (32.4% 1y) (0.0% 2d) (-0.9% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 35,409,422
http://www.evogene.com
Sec Filling | Patents | 143 employees

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industry, and Human. The Agriculture segment engages in the development of seed traits, agrochemical products, and agrobiological products to improve plant performance. The Industry segment engages in the development of castor bean seeds to serve as a feedstock source for biofuel and other industrial uses. The Human segment engages in the discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.

seeds computational israel agricultural msa agriculture

add to watch list Paper trade email alert is off

Akouos, Inc.

AKUS | $13.29 1.07% 3.46%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2022-11-11
Market Cap:
http://www.akouos.com
Sec Filling | Patents | 54 employees

Akouos, Inc. engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA.

gene therapies t-cell genetic hearing loss ceiling

add to watch list Paper trade email alert is off

Forma Therapeutics Holdings, Inc.

FMTX | $20.01 -0.15%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2022-11-09
Market Cap: $ 957,529,666
https://formatherapeutics.com
Sec Filling | Patents | 105 employees

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA.

cancer prostate cancer t-cell treatment ceiling

add to watch list Paper trade email alert is off

Freeline Therapeutics Holdings plc

FRLN | $6.48 0.0% 0

Health Technology

(0.0% 1d) (0.0% 1m) (13.5% 1y) (0.0% 2d) (0.2% 3d) (0.0% 7d) (220.04% volume)
Earnings Calendar:
Market Cap: $ 15,761,239
https://freelinetx.com
Sec Filling | Patents | 177 employees

(United Kingdom) Freeline Therapeutics Holdings Plc operates as holding company whose subsidiaries provide biotechnology services. It develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Nathwani on April 3, 2020 and is headquartered in Stevenage, the United Kingdom.

gene therapies bleeding

add to watch list Paper trade email alert is off

Global Blood Therapeutics, Inc.

GBT | $68.49 0.02% -0.02%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (73.96% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 4,621,443,500
http://www.gbt.com
Sec Filling | Patents | 352 employees

(US) Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.

t-cell ceiling

Drugs

OXBRYTA (Voxelotor)

add to watch list Paper trade email alert is off

Meridian Bioscience Inc.

VIVO | $33.97 0.0% 0

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.7% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar: 2023-02-03
Market Cap: $ 1,488,831,011
http://www.meridianbioscience.com
Sec Filling | Patents | 750 employees

(US) Meridian Bioscience, Inc. engages in the development, manufacture, sale, and distribution of diagnostic test kits, antigens, reagents, and related products. It operates through the following segments: Diagnostics and Life Science. The Diagnostics segment consists testing platforms and technologies such as Isothermal DNA Amplification, Rapid Immunoassay, Enzyme-linked Immunoassay, and Anodic Stripping Voltammetry. The Life Science segment distributes bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.

antibody t-cell diagnostics ceiling

add to watch list Paper trade email alert is off

Mirati Therapeutics, Inc.

MRTX | $58.7 -0.17% 0.34% 0

Health Technology

(0.0% 1d) (0.0% 1m) (36.0% 1y) (0.0% 2d) (-0.1% 3d) (0.0% 7d) (-41.54% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 4,117,670,342
http://www.mirati.com
Sec Filling | Patents | 111 employees

(US) Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.

cancer immunology genetic

add to watch list Paper trade email alert is off